Alamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alamar Biosciences, Inc. ( ALMR ) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 4:05 PM EDT Company Participants Yuling Luo - Co-Founder, Chairman & CEO Justin McAnear - Chief Financial Officer Presentation Unknown Analyst Thank you very much for everyone for being here. It's my pleasure to have the Alamar team with us here today. Yuling Luo, the Chief Executive Officer; and Justin McAnear, the Chief Financial Officer. So, Yuling, Justin, welcome. Yuling Luo Co-Founder, Chairman & CEO Thank you. Justin McAnear Chief Financial Officer Thank you. Question-and-Answer Session Unknown Analyst So, maybe just to start off, for an investor that might be new to the Alamar story, what's the best way to understand where the company is at today, and kind of how you fit into the broader ecosystem? Yuling Luo Co-Founder, Chairman & CEO Alamar is establishing a gold standard in protein detection and analysis. We all know proteomics has a huge potential to improve our understanding of health and disease, leading to better treatment and healthier life. Despite all the great promise, this market remains to be largely untapped, mainly due to the limitation of the current technologies. The current proteomics solution is highly fragmented. On one end of solution, you have those high-plex discovery technologies like mass spec or affinity-based high-plex solutions. They're good for discovery, but they are not built for translation and diagnostics. So the analytical performance are limiting, either like sensitivity or specificity, or workflow are complicated. On the other hand, you have those clinical-grade single-plex immunodiagnostic assays that underlie the $20 billion diagnostic market, but their sensitivity are limited. They cannot multiplex. And that's how we are going to change the game with our precision proteomics platform that will make changes in 2 aspects. The first aspect is analytical performance. So, we built a precision proteomics platform that combines 5